Guidance and quality standards In consultation
Showing 1 to 2 of 2
Title | Consultation | Type | Consultation end date |
---|---|---|---|
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132] | Draft guidance | Technology appraisal guidance | |
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170] | Draft guidance | Technology appraisal guidance |